Zenas BioPharma, Inc.

Name: Zenas BioPharma, Inc. standardized financial statements, quarterly
Creator: Listed

ZBIONasdaqCIK 1953926HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.0m, Q2 FY2026

Operating income−$107.7m, Q2 FY2026

Net income−$111.5m, Q2 FY2026

Zenas BioPharma, Inc., income statement, quarterly
Line item	Unit	period not labelled2023-09-30	period not labelled2023-12-31	period not labelled2024-03-31	period not labelled2024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	50.0	0.0	not reported	0.0	0.0	5.0	10.0	0.0	0.0	0.0	not reported	1.0
Research and development	$m	9.4	20.4	22.6	33.8	33.5	49.2	34.9	43.0	34.4	55.7	60.4	62.9
Operating income	$m	35.6	(24.8)	(27.6)	(39.7)	(41.0)	(55.6)	(37.3)	(55.2)	(52.6)	(238)	(77.4)	(108)
Income tax	$m	not reported	not reported	not reported	not reported	not reported	not reported	(0.2)	0.0	0.0	0.1	not reported	0.1
Net income	$m	35.6	(24.6)	(27.8)	(38.0)	(38.6)	(52.6)	(33.6)	(52.2)	(51.5)	(240)	(81.0)	(111)
Diluted EPS	$ per share	1.96	not reported	(17.89)	(24.23)	(5.02)	not reported	(0.80)	(1.25)	(1.22)	not reported	(1.46)	(1.77)
Basic EPS	$ per share	2.42	not reported	(17.89)	(24.23)	(5.02)	not reported	(0.80)	(1.25)	(1.22)	not reported	(1.46)	(1.77)

Balance sheet

Cash and equivalents$196.6m, Q2 FY2026

Long-term debt$78.6m, FY2025

Shareholders' equity$247.1m, Q2 FY2026

Zenas BioPharma, Inc., balance sheet, quarterly
Line item	Unit	period not labelled2023-09-30	period not labelled2023-12-31	period not labelled2024-03-31	period not labelled2024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	72.3	56.9	37.2	184	360	320	197	44.0	116	111	500	197
Current assets	$m	not reported	59.8	not reported	not reported	394	356	318	279	297	351	730	654
Total assets	$m	not reported	68.2	not reported	not reported	403	370	334	293	322	384	748	702
Current liabilities	$m	not reported	23.3	not reported	not reported	44.0	57.3	49.1	53.2	52.4	62.6	61.2	65.8
Total liabilities	$m	not reported	43.8	not reported	not reported	44.0	57.5	49.4	53.5	126	141	412	455
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	73.0	78.6	not reported	not reported
Shareholders' equity	$m	(202)	(226)	(252)	(289)	359	312	284	240	196	242	336	247

Cash flow

Operating cash flow−$57.2m, Q2 FY2026

Capital expenditure$0, Q2 FY2026

Zenas BioPharma, Inc., cash flow, quarterly
Line item	Unit	period not labelled2023-12-31	period not labelled2024-03-31	period not labelled2024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(15.4)	(19.1)	(31.0)	(31.1)	(38.6)	(37.1)	(41.7)	(41.1)	(52.4)	(75.2)	(57.2)
Capital expenditure	$m	not reported	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0

Diluted shares (weighted)63.11m, Q2 FY2026

Zenas BioPharma, Inc., shares, quarterly
Line item	Unit	period not labelled2023-09-30	period not labelled2024-03-31	period not labelled2024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	1.9	1.6	1.6	7.7	41.8	41.9	42.2	55.6	63.1

Shares outstanding: 65.18m at Jul 31, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.